Trobalt - summary of medicine characteristics

1. NAME OF THE MEDICINAL PRODUCT

Trobalt 50 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 50 mg of retigabine.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Film-coated tablet.

Purple, round, film-coated tablets of 5.6 mm, marked with “RTG 50” on one side.

4. CLINICAL PARTICULARS4.1 Therapeutic indications

Trobalt is indicated as adjunctive treatment of drug-resistant partial onset seizures with or without secondary generalization in patients aged 18 years or older with epilepsy, where other appropriate combinations with other medicinal products have proved inadequate or have not been tolerated.

4.2 Posology and method of administration

Posology

Trobalt must be titrated, according to individual patient response, in order to optimise the balance between efficacy and tolerability.

The maximum total daily starting dose is 300 mg (100 mg three times daily). Thereafter, the total daily dose is increased by a maximum of 150 mg every week, according to the individual patient response and tolerability. An effective maintenance dose is expected to be between 600 mg/day and 1,200 mg/day.

The maximum total maintenance dose is 1,200 mg/day. The safety and efficacy of doses higher than 1,200 mg/day have not been established.

If patients miss one dose or more, it is recommended that they take a single dose as soon as they remember.

After taking a missed dose, at least 3 hours should be allowed before the next dose and then the normal dosing schedule should be resumed.

When withdrawing Trobalt, the dose must be gradually reduced over a period of at least 3 weeks (see section 4.4).

Elderly (65 years of age and above)

There are only limited data on the safety and efficacy of retigabine in patients aged 65 years and above. A reduction in the initial and maintenance dose of Trobalt is recommended in elderly patients.

The total daily starting dose is 150 mg/day and during the titration period the total daily dose should be increased by a maximum of 150 mg every week, according to the individual patient response and tolerability. Doses greater than 900 mg/day are not recommended (see sections 4.4 and 5.2).

Renal impairment

Retigabine and its metabolites are eliminated principally by renal excretion.

No dose adjustment is required in patients with mild renal impairment (creatinine clearance 50 to 80 ml/min; see section 5.2).

A 50% reduction in the initial and maintenance dose of Trobalt is recommended in patients with moderate or severe renal impairment (creatinine clearance <50 ml/min; see section 5.2). The tota daily starting dose is 150 mg, and it is recommended that during the titration period, the total dai dose is increased by 50 mg every week, to a maximum total dose of 600 mg/day.

For patients with end-stage renal disease receiving haemodialysis, the three daily dos

taken as usual on the dialysis day. In addition, a single supplemental dose is rec immediately after haemodialysis. If breakthrough seizures occur towards the e additional supplemental dose may be considered at the start of subsequent

Hepatic impairment

No dose reduction is required in patients with mild hepatic impairment (Child-Pugh score 5 to 6; see section 5.2).

A 50% reduction in the initial and maintenance dose of Trobalt is recommended in patients with moderate or severe hepatic impairment (Child-Pugh score ¿7; see section 5.2). The total daily starting dose is 150 mg, and it is recommended that duri titration period, the total daily dose is increased by 50 mg every week, to a maximum total dose dren below 18 years of age has not yet been established acokinetic data are described in section 5.2, but no e made.

Method of administrati onn

Trobalt is for oral use. The tablets must be taken in three divided doses each day. The tablets should be swallowed whole, and not chewed, crushed or divided.

e taken with or without food (see section 5.2).

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Eye disorders

Pigment changes (discolouration) of ocular tissues, including the retina have been reported in longterm clinical studies with retigabine, sometimes but not always in conjunction with pigment changes of the skin, lips or nails (see below paragraph and section 4.8). Reversibility of retinal pigmentation after retigabine discontinuation has been reported in some subjects. The long-term prognosis of these findings is currently unknown, but some of the reports have been associated with visual impairment.

In addition a distinct form of macular abnormality with features of vitelliform maculopathy (see section 4.8) has also been identified, in most cases diagnosed with optical coherence tomography (OCT) imaging. The rate of progression of vitelliform maculopathy and its-impact on retinal and macular function and vision is unclear. Vision abnormalities (field constriction, loss of central sensitivity, and reduced visual acuity) have been reported.

All patients should undergo comprehensive ophthalmological examinations at baseline and at least every six months, which should include visual acuity, slit-lamp examination, dilated fundus photography, and macular OCT imaging. If retinal pigment changes, vitelliform maculopathy or vision changes are detected, treatment with Trobalt should only be continued after a careful re-assessment of the balance of benefits and risks. If continued, the patient should be monitored more closely.

Skin disorders

Pigment changes (discolouration) of the skin, lips or nails have been reported i studies with retigabine, sometimes but not always in conjunction with pigment tissues (see above paragraph and section 4.8). In patients who develop thes Trobalt should only be continued after a careful re-assessment of the bal

Urinary retention

Urinary retention, dysuria and urinary hesitation were reported in controlled clinical studies with retigabine, generally within the first 8 weeks of treatment     section 4.8). Trobalt must be used with

caution in patients at risk of urinary retention, and it is rec     ended that patients are advised about

the risk of these possible effects.

QT interval

Confusional state, psychotic disorders and hallucinations were reported in controlled clinical studies with retigabine (see section 4.8). These effects generally occurred within the first 8 weeks of treatment, and frequently led to treatment withdrawal in affected patients. It is recommended that patients are advised about the risk of these possible effects.

Suicide risk

Suicidal ideation and behaviour have been reported in patients treated with antiepileptic agents in several indications. A meta-analysis of randomised placebo-controlled trials of antiepileptic medicinal products has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for retigabine.

Therefore, patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice if signs of suicidal ideation or behaviour emerge.

Elderly (65 years of age and above)

Elderly patients may be at increased risk of central nervous system events, urinary retenti fibrillation. Trobalt must be used with caution in this population and a reduced initial maintenance dose is recommended (see sections 4.2 and 5.2).

Withdrawal seizures

Trobalt must be withdrawn gradually to minimise the potential for rebound seizures. It is recommended that the Trobalt dose is reduced over a period of at least 3 weeks, unless safety concerns require an abrupt withdrawal (see section 4.2).

Laboratory tests

Retigabine has been shown to interfere with clinical lab bilirubin, which can result in falsely elevated readings.

4.5 Interaction with other medicinal products and other forms of interaction

Interaction studies have only been p

Other antiepileptic m edicinal products

In vitro data indicated a low potential for interaction with other antiepileptic medicinal products (see section 5.2). The drug interaction potential was, therefore, evaluated based on a pooled analysis across clinical studies and whilst not considered as robust as stand-alone clinical interaction studies, the results support the in vitro data.

Based on these pooled data, retigabine did not cause clinically significant effects on the plasma trough concentrations of the following antiepileptic medicinal products:

• – carbamazepine, clobazam, clonazepam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, pregabalin, topiramate, valproate, zonisamide.

Further, based on pooled data, there were no clinically significant effects of the following antiepileptic medicinal products on retigabine pharmacokinetics:

• – lamotrigine, levetiracetam, oxcarbazepine, topiramate, valproate.

This analysis also showed no clinically significant effect of the inducers (phenytoin, carbamazepine and phenobarbital) on retigabine clearance.

However, steady-state data from a limited number of patients in smaller phase II studies indicated that: – phenytoin can reduce retigabine systemic exposure by 35% – carbamazepine can reduce retigabine systemic exposure by 33%

Interaction with digoxin

Data from an in vitro study showed that the N-acetyl metabolite of retigabine (NAMR) inhibited P-glycoprotein-mediated transport of digoxin in a concentration-dependent manner.

Based on a study conducted in healthy volunteers, therapeutic doses of retigabine (600–1,200 mg/day) resulted in a minor (8–18%) increase in digoxin AUC following a single oral dose of digoxin. The increase did not appear to be dependent on retigabine dose and is not considered clinically relevant. There was no meaningful change in digoxin Cmax. No dose adjustment of digoxin is needed.

Interaction with anaesthetics

Trobalt may increase the duration of anaesthesia induced by some anaesthetics (for example thi sodium; see section 5.1).

Interaction with alcohol

Co-administration of ethanol (1.0 g/kg) with retigabine (200 mg) resulted in an increase in visual blurring in healthy volunteers. It is recommended that patients are adv            e possible effects

on vision if they take Trobalt with alcohol.

Oral contraceptives

At retigabine doses of up to 750 mg/day, there was no clinically si

pharmacokinetics of the estrogen (ethinyl estradiol) or proge oral contraceptive pill. In addition, there was no clinically combination oral contraceptive pill on the pharmacokineti

4.6 Fertility, pregnancy and lactation

Pregnancy

Risk related to antiepileptic medicinal products in general

Specialist advice should be given to women who are of childbearing potential. The need for treatment with antiepileptic medicinal products should be reviewed when a woman is planning to become pregnant. In women being treated for epilepsy, sudden discontinuation of antiepileptic medicine therapy should be avoided as this may lead to breakthrough seizures that could have serious consequences for the woman and the unborn child.

The risk of congenital malformations is increased by a factor of 2 to 3 in the offspring of mothers treated with antiepileptic medicinal products compared with the expected incidence in the general population of approximately 3%. The most frequently reported defects are cleft lip, cardiovascular malformations and neural tube defects. Therapy with multiple antiepileptic medicinal products is associated with a higher risk of congenital malformations than monotherapy and therefore monotherapy should be used whenever possible.

Risk related to Trobalt

There are no adequate data from the use of retigabine in pregnant women. Animal studies are insufficient with respect to reproductive toxicity because the plasma levels achieved in these studies were less than those reached in humans at recommended doses (see section 5.3). In a developmental study in rats whose mothers were treated with retigabine during pregnancy, there was a delay in auditory startle response development of the offspring (see section 5.3). The clinical significance of this finding is not known.

Trobalt is not recommended during pregnancy and in women of childbearing age, not using contraception.

Breastfeeding

It is unknown whether retigabine is excreted in human breast milk. Animal studies have shown excretion of retagabine and/or its metabolites in breast milk. A decision on whether to continue/discon­tinue breast-feeding or to continue/discon­tinue therapy with Trobalt should be made taking into account the benefit of breast-feeding to the child and the benefit of Trobalt therapy to the woman.

Fertility

There were no treatment-related effects of retigabine on fertility in animal studies. However, the plasma levels achieved in these studies were less than those reached in humans at recommended (see section 5.3).

The effect of retigabine on human fertility has not been established.

4.7 Effects on ability to drive and use machines

Adverse reactions such as dizziness, somnolence, diplopia and blurred vision were reported in controlled clinical studies, particularly during titration (see section 4.8). It is recommended that patients are advised about the risk of such adverse reactions at treatment initiation and following each

titration step, and that they are advised not to drive or operate mac how Trobalt affects them.

4.8 Undesirable effects

Summary of the safety profile

In pooled safety data from three multicentre, randomised, double-blind, placebo-controlled studies, adverse reactions were generally mild to m     te in intensity, and were most commonly reported in apparent dose-relationship for dizziness, somnolence, bnormal, tremor, balance disorder, memory impairment, gait

Adverse reactions that were most frequently reported to lead to discontinuation were dizziness, somnolence, fatigue and confusional state.

Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

System Organ Class	Very common	Common	Uncommon
Metabolism and nutrition disorders		Weight increased Increased appetite
Psychiatric disorders		Confusional state Psychotic disorders Hallucinations Disorientation Anxiety
Nervous system disorders	Dizziness Somnolence	Amnesia Aphasia Coordination abnormal Vertigo Paraesthesia Tremor Balance disorder Memory impairment Dysphasia Dysarthria Disturbance in attention Gait disturbance Myoclonus	Hypokinesia •
Eye disorders	Pigment changes (discolouration) of ocular tissues, including the retina, have been observed after several years of treatment. Some of these reports have been associated with visual impairment.	Diplopia Blurred vision Acquired Vitelliform Maculopathy
Gastrointestinal disorders		Nausea Constipation Dyspepsia Dry mouth	Dysphagia
Hepatobiliary disorders		Increased liver function tests

System Organ Class	Very common	Common	Uncommon	&
Skin and subcutaneous disorders	Blue-grey discolouration of the nails, lips and/or skin have been observed, generally at higher doses and after several years of treatment.		Skin rash Hyperhidrosis
Renal and urinary disorders		Dysuria Urinary hesitation Haematuria Chromaturia	Urinary retention ’G Nephrolithiasis	I
General disorders and administrative site conditions	Fatigue	Asthenia Malaise Peripheral oedema

Description of selected adverse reactions

Adverse reactions related to voiding dysfunction, including urinary retention, were reported in 5% of retigabine-treated patients in the pooled safety dataset (see section 4.4). The majority of events occurred in the first 8 weeks of treatment, and there was no apparent dose-relationship.

In retigabine-treated patients in the pooled dataset, confusional state was reported in 9% of patients, hallucinations in 2% of patients and psychotic disorders in 1% of patients (see section 4.4). The majority of adverse reactions occurred in the first 8 weeks of treatment, and there was an apparent dose-relationship for confusional state only.

Adverse event data from clinical trial subjects showed a rate of event of discolouration of the nails, lips, skin and/or mucosa per patient year of exposure of 3.6%. The cumulative incidences of an event at 1 year, 2 years, 3 years, 4 years and 5 years of exposure are approximately 1%, 1.8%, 4.4%, 10.2% and 16.7% respectively.

Approximately 30–40% of clinical trial subjects who were being treated with retigabine and underwent a skin and/or ophthalmological examination had findings of discolouration of nails, lips, skin and/or mucosa or non-retinal ocular pigmentation, and approximately 15–30% of clinical trial subjects who were being treated with retigabine and underwent an ophthalmological examination had retinal pigmentation findings. In addition, cases of acquired vitelliform-type maculopathy have been identified, both in clinical studies and as spontaneous reports.

Data from elderly patients indicates that they may be more likely to experience certain central nervous system events, including somnolence, amnesia, coordination abnormal, vertigo, tremor, balance disorder, memory impairment and gait disturbance.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

Symptoms and signs

There is limited experience of overdose with retigabine.

Retigabine overdoses in excess of 2,500 mg/day were reported during clinical studies. In addition to adverse reactions seen at therapeutic doses, symptoms of retigabine overdose included agitation, aggressive behaviour and irritability. There were no reported sequelae.

In a study in volunteers, cardiac arrhythmia (cardiac arrest/asystole or ventricular tachycardia) occurred in two subjects within 3 hours of receiving a single 900 mg retigabine dose. The arrhyth spontaneously resolved, and both volunteers recovered without sequelae.

Management

In the event of overdose, it is recommended that the patient is given appropriate supportive therapy as clinically indicated, including electrocardiogram (ECG) monitoring. Further management should be as recommended by the national poisons centre, where available.

Haemodialysis has been shown to reduce the plasma concentrations of retigabine and NAMR by approximately 50%.

5. PHARMACOLOGICAL PROPERTIES5.1 Pharmacodynamic properties

Pharmacotherapeutic group: antiepileptics, other ntiepileptics, ATC code: N03AX21.

Mechanism of action

ated ion channels found in neuronal cells and are In vitro studies indicate that retigabine acts primarily

ls (KCNQ2 [Kv7.2] and KCNQ3 [Kv7.3]). This stabilises

the resting membrane potential and controls the sub-threshold electrical excitability in neurons, thus preventing the initiation of ptiform action potential bursts. Mutations in the KCNQ channels underlie several human inhle disorders, including epilepsy (KCNQ2 and 3). The mechanism of action of retigabine on potassium channels has been well documented, however other mechanisms by which retigabine may assert an antiepileptic effect have yet to be fully elucidated.

In a range of seizure models, retigabine increased the threshold for seizure induction produced by maximal electroshock, pentylenetetrazol, picrotoxin and N-methyl-D-aspartate (NMDA). Retigabine also displayed inhibitory properties in multiple kindling models, for example, in the fully kindled state and in some cases during the kindling development. In addition, retigabine was effective in preventing status epilepticus seizures in rodents with cobalt-induced epileptogenic lesions, and inhibiting tonic extensor seizures in genetically susceptible mice. The relevance of these models to human epilepsy, however, is not known.

Pharmacodynamic effects

In rats, retigabine increased the sleep time induced by thiopental sodium from approximately 4 min to 53 min, and the propofol-induced sleep time from approximately 8 min to 12 min. There was no effect on sleep time induced by halothane or methohexital sodium. Retigabine may increase the duration of anaesthesia induced by some anaesthetics (for example thiopental sodium).

Clinical efficacy of adjunctive retigabine therapy in partial onset seizures

Three multicentre, randomized, double-blind, placebo-controlled studies in a total of 1239 adult patients have been conducted to assess the efficacy of retigabine as adjunctive therapy of partial onset seizures, with or without secondary generalisation. All patients enrolled were to have had seizures that were not adequately controlled with 1 to 3 concomitant antiepileptic medicinal products, and more than 75% of all patients were taking >2 concurrent antiepileptic medicinal products. Across all studies, patients had a mean duration of epilepsy of 22 years and a median baseline seizure frequency ranging from 8 to 12 per 28 days. Patients were randomized to placebo or retigabine at 600, 900 or 1,200 mg/day (see Table 1). During an 8-week baseline period, patients had to experience >4 partial onset seizures per 28 days. Patients could not be seizure-free for >21 days. The duration of the maintenance phase was 8 or 12 weeks.

The primary efficacy endpoints were:

• – percentage change in the 28-day total partial seizure frequency from baseline to the double-blind phase (titration and maintenance phases combined) in all three studies

• – responder rate (defined as the percentage of patients with a >50% reduction in 28-day total partial seizure frequency) from baseline to the maintenance phase (Studies 301 and 302 only).

Retigabine was effective in adjunctive treatment of adults with partial onset seizures in three clinical studies (Table 1). Retigabine was statistically significantly superior to placebo at 600 mg/day (one study), 900 mg/day (two studies) and 1,200 mg/day (two studies).

The studies were not designed to evaluate specific combinations of antiepileptic medicinal products. Consequently, the efficacy and safety of retigabine when taken concomitantly with antiepileptic medicinal products that were less commonly used as background treatment in the clinical studies, including levetiracetam, has not been definitely shown.

Table 1. Summary of percentage changes in 28-d ay totalpartial seizure frequency and responder rates

Study (n=population in double-blind phase; n=population in maintenance phase )	Placebo	Retigabine
		600 mg/day	900 mg/day	1,200 mg/day
Study 205 (n=396; n=303 ) „¿V
Total partial seizure frequency (median) % change	–13%	–23%	–29%*	–35%*
Responder rate (secondary endpoint)	26%	28%	41%	41%*
Study 301 (n=305; n= 256)
Total partial seizure frequency (median) % change	–18%	~	~	–44%*
Responder rate	23%	~	~	56%*
Study 302 (n=538; n=471 )
Total partial seizure frequency (median) % change	–16%	–28%*	–40%*	~
Responder rate	19%	39%*	47%*	~

Statistically significant, p<0.05

Dose not studied

In open-label extensions of the three placebo-controlled studies, persistence of efficacy was maintained over an evaluation period of at least 12 months (365 patients).

Paediatric population

The European Medicines Agency has waived the obligation to submit the results of studies with Trobalt in paediatric patients aged 0 to below 2 years with Lennox Gastaut Syndrome (see section 4.2 for information on paediatric use).

The European Medicines Agency has deferred the obligation to submit the results of studies with Trobalt in paediatric patients aged 2 to below 18 years with Lennox Gastaut Syndrome, and in paediatric patients aged 0 to below 18 years with partial onset seizures (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

Absorption                                   4

After both single and multiple oral doses, retigabine is rapidly absorbed with median tmax values generally between 0.5 and 2 hours. Absolute oral bioavailability of retigabine relative to an intravenous dose is approximately 60%.

Administration of retigabine with a high fat meal resulted in no change in the overall extent of retigabine absorption, but food reduced the between-subject variability in Cmax (23%) compared to the fasted state (41%), and led to an increase in Cmax (38%). The effect of food on Cmax under usual clinical conditions is not expected to be clinically relevant. Therefore Trobalt may be taken with or without food.

Distribution

Retigabine is approximately 80% bound to plasma protein over the concentration range of 0.1 to 2 ^g/ml. The steady state volume of distribution of retigabine is 2 to 3 l/kg following intravenous dosing.

Biotransformation

Retigabine is extensively metabolised in humans. A substantial fraction of the retigabine dose is converted to inactive N-glucuronides. Retigabine is also metabolised to an N-acetyl metabolite (NAMR) that is also subsequently glucuronidated. NAMR has antiepileptic activity, but is less potent than retigabine in animal seizure models.

There is no evidence for hepatic oxidative metabolism of retigabine or NAMR by cytochrome P450 enzymes. Therefore, co-administration with inhibitors or inducers of cytochrome P450 enzymes is unlikely to affect the pharmacokinetics of retigabine or NAMR.

In vitro studies using human liver microsomes showed little or no potential for retigabine to inhibit the major cytochrome P450 isoenzymes (including CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5). In addition, retigabine and NAMR did not induce CYP1A2 or CYP3A4/5 in human primary hepatocytes. Therefore, retigabine is unlikely to affect the pharmacokinetics of substrates of the major cytochrome P450 isoenzymes through inhibition or induction mechanisms.

Elimination

Elimination of retigabine occurs via a combination of hepatic metabolism and renal excretion. A total of approximately 84% of the dose is recovered in the urine, including the N-acetyl metabolite (18%), N-glucuronides of the parent active substance and of the N-acetyl metabolite (24%), or parent active substance (36%). Only 14% of retigabine is excreted in the faeces. Retigabine has a plasma half-life of approximately 6 to 10 hours. The total clearance of retigabine from plasma following intravenous dosing is typically 0.4 to 0.6 l/h/kg.

Linearity

Retigabine pharmacokinetics are essentially linear over the single-dose range of 25 to 600 mg in healthy volunteers and up to 1,200 mg daily in patients with epilepsy, with no unexpected accumulation following repeated administration.

Special patient populations

Renal impairment

In a single-dose study, retigabine AUC was increased by approximately 30% innteers with mild renal impairment (creatinine clearance 50 to 80 ml/min) and by approximately 100% in volunteers with moderate to severe renal impairment (creatinine clearance <50      n), relative to healthy

volunteers. Adjustment of the Trobalt dose is recommended in patiith moderate to severe renal impairment but no adjustment of the Trobalt dose is recommendtients with mild renal impairment (see section 4.2).

In a single-dose study in healthy volunteers and subjects with end stage renal disease, the retigabine AUC was increased by approximately 100% in the subjects with end stage renal disease relative to healthy volunteers.

In a second single-dose study in subjects with end stage renal disease receiving chronic haemodialysis (n= 8), initiation of dialysis at approximately 4 hours after a single dose of retigabine (100 mg) resulted in a median reduction in retigabine plasma concentrations of 52% from the start to end of dialysis. The percentage decrease in plasma concentration during dialysis ranged from 34% to 60% except for one subject who had a 17% reduction.

ere no clinically significant effects on retigabine AUC in volunteers (Child-Pugh score 5 to 6). The retigabine AUC was increased by nteers with moderate hepatic impairment (Child-Pugh score 7 to 9) and by 0% in volunteers with severe hepatic impairment (Child-Pugh score >9), relative to s. Adjustment of the Trobalt dose is recommended in patients with moderate or pairment (see section 4.2).

Body weight

In a population pharmacokinetic analysis, retigabine clearance increased with increasing body surface area. However, this increase is not considered to be clinically meaningful, and since retigabine is titrated according to individual patient response and tolerability, dose-adjustments are not required on the basis of body weight.

Elderly (65 years of age and above)

In a single-dose study, retigabine was eliminated more slowly by healthy elderly volunteers (66 to 82 years of age) relative to healthy young adult volunteers, resulting in a higher AUC (approximately 40 to 50%) and longer terminal half-life (30%) (see section 4.2).

5.3 Preclinical safety data

Reproductive toxicology

Retigabine had no effect on fertility or general reproductive performance.

ine and/or its metabolites crossed the placenta resulting in tissue concentrations that ilar in dams and foetuses.

There was no evidence of teratogenicity following administration of retigabine to pregnant animals during the period of organogenesis. In a study of peri- and post-natal development in rats, retigabine was associated with increased perinatal mortality following administration during pregnancy. In addition, there was a delay in auditory startle response development. These findings were apparent at exposure levels lower than those obtained with clinically recommended doses and were accompanied by maternal toxicities (including ataxia, hypokinesia, tremor and reduced body weight gain). The maternal toxicities interfered with higher dosing of the dams and hence deduction of safety margins with regard to human therapy.

6. PHARMACEUTICAL PARTICULARS6.1 List of excipients

Tablet core

Croscarmellose sodium

Hypromellose

Magnesium stearate

Microcrystalline cellulose.

6.4 Special precautions for storage

Film-coating

6.2 Incompatibilities

Not applicable.

3 years

6.3 Shelf life

foil blisters. Packs containing 21or 84 film-coated tablets.

marketed.

quirements.

50 mg tablets:

Polyvinyl alcohol

Titanium dioxide (E171)

Talc (E553b)

Indigo carmine aluminium lake (E132)

Carmine (E120).

Lecithin (SOY)

Xanthan gum

50 mg tablets:

Opaque PVC-PVDC-a

No sp

7. MARKETING AUTHORISATION HOLDER

Glaxo Group Limited 980 Great West Road, Brentford, Middlesex, TW8 9GS United Kingdom

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/11/681/001, EU/1/11/681/002

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 28 March 2011

Date of latest renewal: 14 January 2016